Virus antigen-derived immunogenic peptides and their use for the early intervention and treatment of liver cancer

WO2026136319A1PCT designated stage Publication Date: 2026-06-25THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
Filing Date
2025-12-16
Publication Date
2026-06-25

AI Technical Summary

Technical Problem

Hepatocellular carcinoma (HCC) is a significant global health concern with complex etiologies, lacking a unified prevention strategy, and the role of host factors in preventing carcinogenesis is unclear, while some viruses have shown potential oncolytic properties for tumor therapy.

Method used

Immunogenic peptides derived from Enterovirus genus antigens, specifically the CE1 peptide, are used to induce T-cell activation and kill HCC cells through HLA-specific interactions, administered via mRNA vaccines or lipid nanoparticles, potentially as an early intervention for liver cancer.

Benefits of technology

The immunogenic peptides enhance T-cell activation and cytotoxicity against HCC cells, demonstrating a protective effect against liver cancer development and improved prognosis, particularly in high-risk populations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025059785_25062026_PF_FP_ABST
    Figure US2025059785_25062026_PF_FP_ABST
Patent Text Reader

Abstract

A unique set of viral antigens with serological responses that are significantly reduced in patients with hepatocellular carcinoma (HCC) were identified by profiling pan-viral serological repertoires among 2,647 study subjects. A common epitope (CE1) shared among reactive viral antigens belonging to the rhinovirus and enterovirus families was identified. Administration of the CE1 peptide induced cytolytic activity of T cells and killing of HCC tumor cells. Immunogenic peptides and compositions based on the CE1 peptide, and their use for the treatment, early intervention and prophylaxis of liver cancer (such as HCC or cholangiocarcinoma), are described.
Need to check novelty before this filing date? Find Prior Art